ZURA Zura Bio Limited
USHealthcareAs of 2026-08-24
Why ZURA matters now
Zura Bio Limited (ZURA) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.30 with +7.69% on the session and $598.5M in market capitalization; recent performance reads 1-month -6.01% and YTD -28.44%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-24.2M, and EPS of $-0.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -29.8%.
The latest indexable market news headline is "Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $15.00; recent insider activity includes Kulkarni Sandeep Chidambar filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.94
P/S
0.00
EV/EBITDA
-0.24
DCF Value
$1.15
FCF Yield
-29.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-54.6%
ROA
-33.0%
ROIC
-37.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-24.2M | $-0.22 |
| Q4 2025 | $0.00 | $-17.2M | $-0.49 |
| FY 2025 | $0.00 | $-68.7M | $-1.06 |
| Q3 2025 | $0.00 | $-18.0M | $-0.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$15.00
Target (Median)
$15.00
Target Range
$15.00 - $15.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.03
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.